Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Max Heiduk

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7907-4162; OpenAlex author ID A5089043475. Sources: OpenAlex.

Their work

Papers
12 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
27
Papers, trials and grants by year

2020: 3 papers · 2021: 1 paper · 2022: 2 papers · 2023: 3 papers · 2024: none · 2025: 2 papers · 2026: 1 paper

Papers 12

  1. Nectin-4 reduces T cell effector function and is a therapeutic target in pancreatic cancer. Co-author DOI 10.1172/jci.insight.194290↗
  2. Extracellular vesicles from pancreatic cancer and its tumour microenvironment promote increased Schwann cell migration. Co-author DOI 10.1038/s41416-024-02915-0↗
  3. The Value of Blood T Cell Frequencies for Risk Prediction of Postoperative Complications in Pancreatic Cancer Surgery. First author DOI 10.1097/as9.0000000000000545↗
  4. Serum immune checkpoint profiling identifies soluble CD40 as a biomarker for pancreatic cancer. First author DOI 10.1038/s41698-023-00459-9↗
  5. TIGIT Expression Delineates T-cell Populations with Distinct Functional and Prognostic Impact in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-23-0258↗
  6. VISTA Ligation Reduces Antitumor T-Cell Activity in Pancreatic Cancer. Co-author DOI 10.3390/cancers15082326↗
  7. Neoadjuvant chemotherapy drives intratumoral T cells toward a proinflammatory profile in pancreatic cancer. Co-author DOI 10.1172/jci.insight.152761↗
  8. Clinical Significance of Tumor-Infiltrating Conventional and Plasmacytoid Dendritic Cells in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3390/cancers14051216↗
  9. LAG-3-Expressing Tumor-Infiltrating T Cells Are Associated with Reduced Disease-Free Survival in Pancreatic Cancer. Co-author DOI 10.3390/cancers13061297↗
  10. Gamma-delta T cells stimulate IL-6 production by pancreatic stellate cells in pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00432-020-03367-8↗
  11. Detection of pancreatic ductal adenocarcinoma with galectin-9 serum levels. Co-author DOI 10.1038/s41388-020-1186-7↗
  12. PD-1 Expression by Lymph Node and Intratumoral Regulatory T Cells Is Associated with Lymph Node Metastasis in Pancreatic Cancer. Co-author DOI 10.3390/cancers12102756↗

Closest collaborators

The 25 strongest of 27 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Adrian M. Seifert · 12 shared papers, 2020–2026 · strength 1.81
  2. Lena Seifert · 12 shared papers, 2020–2026 · strength 1.81
  3. Jürgen Weitz · 12 shared papers, 2020–2026 · strength 1.81
  4. David Digomann · 7 shared papers, 2021–2026 · strength 1.20
  5. Marius Distler · 4 shared papers, 2020–2025 · strength 0.65
  6. Marc Schmitz · 5 shared papers, 2020–2023 · strength 0.64
  7. Christoph Kahlert · 4 shared papers, 2020–2025 · strength 0.56
  8. Ioana Plesca · 4 shared papers, 2021–2023 · strength 0.54
  9. Loreen Natusch · 2 shared papers, 2025–2026 · strength 0.46
  10. Thilo Welsch · 3 shared papers, 2020 · strength 0.30
  11. Franziska Baenke · 1 shared paper, 2026 · strength 0.24
  12. Daniel E. Stange · 1 shared paper, 2026 · strength 0.24
  13. Sarah Cronjaeger · 1 shared paper, 2026 · strength 0.24
  14. Diane M. Simeone · 1 shared paper, 2026 · strength 0.24
  15. Sebastian Hempel · 1 shared paper, 2025 · strength 0.22
  16. Florian Oehme · 1 shared paper, 2025 · strength 0.22
  17. Christoph Reißfelder · 2 shared papers, 2020 · strength 0.19
  18. Linhan Ye · 1 shared paper, 2025 · strength 0.18
  19. Fang Cheng Wong · 1 shared paper, 2025 · strength 0.18
  20. Mathieu Pecqueux · 1 shared paper, 2025 · strength 0.18
  21. Yi Han · 1 shared paper, 2025 · strength 0.18
  22. Bo Kong · 1 shared paper, 2025 · strength 0.18
  23. İhsan Ekin Demir · 1 shared paper, 2025 · strength 0.18
  24. Michael B. Ghadimi · 1 shared paper, 2023 · strength 0.16
  25. Jochen Gaedcke · 1 shared paper, 2023 · strength 0.16

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.